- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Belite Bio Inc ADR (BLTE)
NASDAQ
Symbol | Exchange | Currency |
|---|
29.60
-1.17(-3.80%)
After Hours
29.60
0.00(0.00%)
- Real-time Data
- Volume:47,295
- Day's Range:29.12 - 31.00
- 52 wk Range:8.80 - 44.70
BLTE Overview
- Prev. Close
- 30.77
- Day's Range
- 29.12-31
- Revenue
- -
- Open
- 30.8
- 52 wk Range
- 8.8-44.7
- EPS
- -0.4
- Volume
- 47,295
- Market Cap
- 736.08M
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 86,657
- P/E Ratio
- -
- Beta
- -
- 1-Year Change
- -
- Shares Outstanding
- 24,867,408
- Next Earnings Date
- Nov 30, 2022
What is your sentiment on Belite Bio ADR?
or
Market is currently closed. Voting is open during market hours.
Belite Bio Inc ADR News
- Belite Bio IPO More than Doubles on Open
- ByInvesting.com-
- 2
Today's IPO for Belite Bio, Inc (BLTE) opened trading at $12.50 after pricing 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00.The Benchmark...
Belite Bio Inc ADR Company Profile
Belite Bio Inc ADR Company Profile
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.60 | 3.70 | 3.36 | +0.220 | +6.51% | 21.02M | NASDAQ | |||
| 80.58 | 80.63 | 78.70 | +1.94 | +2.47% | 605.50K | NASDAQ | |||
| 249.30 | 249.41 | 243.76 | +6.60 | +2.72% | 6.06M | NASDAQ | |||
| 91.88 | 92.03 | 89.25 | +0.36 | +0.39% | 1.11M | NASDAQ | |||
| 396.43 | 407.09 | 393.88 | -0.25 | -0.06% | 552.82K | NASDAQ | |||
| 94.77 | 94.80 | 91.43 | -0.10 | -0.11% | 17.85M | NYSE | |||
| 88.71 | 89.02 | 86.26 | +0.13 | +0.15% | 5.27M | NYSE | |||
| 4.96 | 5.15 | 4.65 | +0.41 | +9.01% | 929.45K | NYSE | |||
| 10.09 | 10.10 | 10.08 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 77.84 | 78.31 | 77.78 | -1.60 | -2.01% | 1.44K | OTC Markets | |||
| 9.90 | 9.90 | 9.89 | +0.010 | +0.10% | 1.15K | NASDAQ | |||
| 23.68 | 23.86 | 23.07 | +0.53 | +2.29% | 575.48K | NYSE | |||
| 4.20 | 4.26 | 3.99 | +0.14 | +3.45% | 103.77K | NASDAQ | |||
| 9.86 | 9.86 | 9.85 | 0.000 | 0.00% | 0.00 | NASDAQ | |||
| 8.75 | 8.84 | 8.68 | +0.07 | +0.81% | 90.35K | NYSE |